vTv Therap | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.08.

EBIT: As of FY2025 Q3, the actual value is USD -11.1 M.

Segment Revenue

• No revenue was reported for the three months ended September 30, 2025, and 2024. For the nine months ended September 30, 2025, no revenue was reported, compared to $1.0 million in the same period in 2024, which was related to a development milestone under the Newsoara License Agreement.

Operational Metrics

• Net Loss: For the three months ended September 30, 2025, the net loss attributable to vTv Therapeutics Inc. was $8.7 million, compared to $4.8 million in the same period in 2024. For the nine months ended September 30, 2025, the net loss was $19.8 million, compared to $14.8 million in 2024.
• Operating Loss: The operating loss for the three months ended September 30, 2025, was $10.7 million, compared to $6.5 million in 2024. For the nine months ended September 30, 2025, the operating loss was $24.9 million, compared to $19.3 million in 2024.
• Research and Development Expenses: For the three months ended September 30, 2025, research and development expenses were $7.0 million, compared to $3.2 million in 2024. For the nine months ended September 30, 2025, these expenses were $14.0 million, compared to $9.3 million in 2024.
• General and Administrative Expenses: For the three months ended September 30, 2025, these expenses were $3.7 million, compared to $3.3 million in 2024. For the nine months ended September 30, 2025, the expenses were $11.0 million, consistent with 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $16.0 million, compared to $20.5 million in 2024.
• Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $77.8 million, compared to $52.6 million in 2024.

Unique Metrics

• Cash and Cash Equivalents: As of September 30, 2025, cash and cash equivalents were $98.5 million, compared to $36.7 million as of December 31, 2024.

Future Outlook and Strategy

• Core Business Focus: The company is focused on the development of cadisegliatin, currently in a Phase 3 trial for type 1 diabetes, with plans to initiate further registrational studies in 2027. The company is also working with G42 Investments to initiate a Phase 2 trial in type 2 diabetes in the Middle East region in the fourth quarter of 2025.
• Non-Core Business: The company is evaluating several financing strategies to increase cash reserves, including direct equity investments and potential licensing and monetization of other clinical development programs.